Table 2

Cardiometabolic characteristics of study subjects in the four growth groups.

MismatchFGD-onlyRPWG-onlyReference
n = 85n = 113n = 186n = 413
Anthropometry and adiposity outcomes
6-y z-BMI (SDS) (n = 674)0.18 ± 1.26−0.16 ± 1.570.66 ± 1.59−0.29 ± 1.06
6-y z-height (SDS) (n = 674)0.50 ± 1.05−0.33 ± 1.000.45 ± 0.97−0.30 ± 0.85
6-y body fat % (n = 310)19.36 ± 5.4719.65 ± 8.2423.57 ± 7.6718.94 ± 5.36
4.5-y SAT (mL) (n = 262)590.32 ± 293.33503.79 ± 337.84807.90 ± 595.04471.77 ± 197.19
4.5-y VAT (mL) (n = 262)200.07 ± 53.07168.24 ± 52.15220.07 ± 124.48181.66 ± 51.82
4.5-y IMCL (% of water signal) (n = 227)0.48 ± 0.130.45 ± 0.200.55 ± 0.440.44 ± 0.21
4.5-y liver fat (% by weight) (n = 216)0.65 ± 0.400.52 ± 0.390.58 ± 0.400.53 ± 0.37
6-y metabolic outcomes
Fasting glucose (mmol/L) (n = 429)4.64 ± 0.434.57 ± 0.344.56 ± 0.334.51 ± 0.36
Fasting insulin (pmol/L) (n = 324)37.35 ± 23.0826.56 ± 12.9835.00 ± 24.6626.69 ± 14.97
HOMA-IR (units) (n = 323)1.17 ± 0.880.78 ± 0.401.03 ± 0.740.77 ± 0.45
6-y cardiovascular outcomes
cIMT (mm) (n = 422)0.43 ± 0.040.42 ± 0.030.42 ± 0.030.42 ± 0.03
PWV (m/s) (n = 443)4.82 ± 1.105.25 ± 2.244.91 ± 1.484.90 ± 1.58
SBP (mmHg) (n = 565)102.80 ± 8.32101.90 ± 9.25101.48 ± 8.48100.23 ± 8.12
DBP (mmHg) (n = 565)61.98 ± 6.8659.83 ± 5.3959.81 ± 5.4959.16 ± 5.48
MismatchFGD-onlyRPWG-onlyReference
n = 85n = 113n = 186n = 413
Anthropometry and adiposity outcomes
6-y z-BMI (SDS) (n = 674)0.18 ± 1.26−0.16 ± 1.570.66 ± 1.59−0.29 ± 1.06
6-y z-height (SDS) (n = 674)0.50 ± 1.05−0.33 ± 1.000.45 ± 0.97−0.30 ± 0.85
6-y body fat % (n = 310)19.36 ± 5.4719.65 ± 8.2423.57 ± 7.6718.94 ± 5.36
4.5-y SAT (mL) (n = 262)590.32 ± 293.33503.79 ± 337.84807.90 ± 595.04471.77 ± 197.19
4.5-y VAT (mL) (n = 262)200.07 ± 53.07168.24 ± 52.15220.07 ± 124.48181.66 ± 51.82
4.5-y IMCL (% of water signal) (n = 227)0.48 ± 0.130.45 ± 0.200.55 ± 0.440.44 ± 0.21
4.5-y liver fat (% by weight) (n = 216)0.65 ± 0.400.52 ± 0.390.58 ± 0.400.53 ± 0.37
6-y metabolic outcomes
Fasting glucose (mmol/L) (n = 429)4.64 ± 0.434.57 ± 0.344.56 ± 0.334.51 ± 0.36
Fasting insulin (pmol/L) (n = 324)37.35 ± 23.0826.56 ± 12.9835.00 ± 24.6626.69 ± 14.97
HOMA-IR (units) (n = 323)1.17 ± 0.880.78 ± 0.401.03 ± 0.740.77 ± 0.45
6-y cardiovascular outcomes
cIMT (mm) (n = 422)0.43 ± 0.040.42 ± 0.030.42 ± 0.030.42 ± 0.03
PWV (m/s) (n = 443)4.82 ± 1.105.25 ± 2.244.91 ± 1.484.90 ± 1.58
SBP (mmHg) (n = 565)102.80 ± 8.32101.90 ± 9.25101.48 ± 8.48100.23 ± 8.12
DBP (mmHg) (n = 565)61.98 ± 6.8659.83 ± 5.3959.81 ± 5.4959.16 ± 5.48

Values in table are presented as mean ± SD or n (%). FGD, fetal growth deceleration; RPWG, rapid postnatal weight gain; BMI, body mass index; SDS, standard deviation score; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; IMCL, intramyocellular lipid; HOMA-IR, homeostasis model assessment of insulin resistance; cIMT, carotid intima-media thickness; PWV, pulse wave velocity; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Table 2

Cardiometabolic characteristics of study subjects in the four growth groups.

MismatchFGD-onlyRPWG-onlyReference
n = 85n = 113n = 186n = 413
Anthropometry and adiposity outcomes
6-y z-BMI (SDS) (n = 674)0.18 ± 1.26−0.16 ± 1.570.66 ± 1.59−0.29 ± 1.06
6-y z-height (SDS) (n = 674)0.50 ± 1.05−0.33 ± 1.000.45 ± 0.97−0.30 ± 0.85
6-y body fat % (n = 310)19.36 ± 5.4719.65 ± 8.2423.57 ± 7.6718.94 ± 5.36
4.5-y SAT (mL) (n = 262)590.32 ± 293.33503.79 ± 337.84807.90 ± 595.04471.77 ± 197.19
4.5-y VAT (mL) (n = 262)200.07 ± 53.07168.24 ± 52.15220.07 ± 124.48181.66 ± 51.82
4.5-y IMCL (% of water signal) (n = 227)0.48 ± 0.130.45 ± 0.200.55 ± 0.440.44 ± 0.21
4.5-y liver fat (% by weight) (n = 216)0.65 ± 0.400.52 ± 0.390.58 ± 0.400.53 ± 0.37
6-y metabolic outcomes
Fasting glucose (mmol/L) (n = 429)4.64 ± 0.434.57 ± 0.344.56 ± 0.334.51 ± 0.36
Fasting insulin (pmol/L) (n = 324)37.35 ± 23.0826.56 ± 12.9835.00 ± 24.6626.69 ± 14.97
HOMA-IR (units) (n = 323)1.17 ± 0.880.78 ± 0.401.03 ± 0.740.77 ± 0.45
6-y cardiovascular outcomes
cIMT (mm) (n = 422)0.43 ± 0.040.42 ± 0.030.42 ± 0.030.42 ± 0.03
PWV (m/s) (n = 443)4.82 ± 1.105.25 ± 2.244.91 ± 1.484.90 ± 1.58
SBP (mmHg) (n = 565)102.80 ± 8.32101.90 ± 9.25101.48 ± 8.48100.23 ± 8.12
DBP (mmHg) (n = 565)61.98 ± 6.8659.83 ± 5.3959.81 ± 5.4959.16 ± 5.48
MismatchFGD-onlyRPWG-onlyReference
n = 85n = 113n = 186n = 413
Anthropometry and adiposity outcomes
6-y z-BMI (SDS) (n = 674)0.18 ± 1.26−0.16 ± 1.570.66 ± 1.59−0.29 ± 1.06
6-y z-height (SDS) (n = 674)0.50 ± 1.05−0.33 ± 1.000.45 ± 0.97−0.30 ± 0.85
6-y body fat % (n = 310)19.36 ± 5.4719.65 ± 8.2423.57 ± 7.6718.94 ± 5.36
4.5-y SAT (mL) (n = 262)590.32 ± 293.33503.79 ± 337.84807.90 ± 595.04471.77 ± 197.19
4.5-y VAT (mL) (n = 262)200.07 ± 53.07168.24 ± 52.15220.07 ± 124.48181.66 ± 51.82
4.5-y IMCL (% of water signal) (n = 227)0.48 ± 0.130.45 ± 0.200.55 ± 0.440.44 ± 0.21
4.5-y liver fat (% by weight) (n = 216)0.65 ± 0.400.52 ± 0.390.58 ± 0.400.53 ± 0.37
6-y metabolic outcomes
Fasting glucose (mmol/L) (n = 429)4.64 ± 0.434.57 ± 0.344.56 ± 0.334.51 ± 0.36
Fasting insulin (pmol/L) (n = 324)37.35 ± 23.0826.56 ± 12.9835.00 ± 24.6626.69 ± 14.97
HOMA-IR (units) (n = 323)1.17 ± 0.880.78 ± 0.401.03 ± 0.740.77 ± 0.45
6-y cardiovascular outcomes
cIMT (mm) (n = 422)0.43 ± 0.040.42 ± 0.030.42 ± 0.030.42 ± 0.03
PWV (m/s) (n = 443)4.82 ± 1.105.25 ± 2.244.91 ± 1.484.90 ± 1.58
SBP (mmHg) (n = 565)102.80 ± 8.32101.90 ± 9.25101.48 ± 8.48100.23 ± 8.12
DBP (mmHg) (n = 565)61.98 ± 6.8659.83 ± 5.3959.81 ± 5.4959.16 ± 5.48

Values in table are presented as mean ± SD or n (%). FGD, fetal growth deceleration; RPWG, rapid postnatal weight gain; BMI, body mass index; SDS, standard deviation score; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; IMCL, intramyocellular lipid; HOMA-IR, homeostasis model assessment of insulin resistance; cIMT, carotid intima-media thickness; PWV, pulse wave velocity; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close